Results 141 to 150 of about 6,309 (194)

'Masked apical sparing' in wild-type transthyretin cardiac amyloidosis complicated by aortic valve stenosis: a case report. [PDF]

Eur Heart J Case Rep
Matsumoto K, Matsuo K, Arai T, Nakano S.
europepmc   +1 more source

Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study. [PDF]

Rev Cardiovasc Med
Raslan MA, Nabi HA, Odeh NB, Alatout MH, Baqal O, Abbas MT, El Masry HZ, Sorajja D.   +7 more
europepmc   +1 more source

Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Crespo-Leiro MG, Hanna M, Damy T, Delgado D, Ebede B, Marino V, Wang R, Maurer MS, Garcia-Pavia P, Drachman BM.   +9 more
europepmc   +1 more source

The evolving landscape of restrictive cardiomyopathy treatment: clinical trial trends and future directions. [PDF]

Front Cardiovasc Med
Deng B, Liu W.
europepmc   +1 more source

Transthyretin Cardiac Amyloidosis With Reduced Ejection Fraction in a 47-Year-Old Man: An Unusual Presentation. [PDF]

Cureus
Moujahid M, Allalat I, Lamtai M, Fellat N.   +3 more
europepmc   +1 more source

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits. [PDF]

Cardiol Ther
Powers ET, Amass L, Baylor L, Fernández-Arias I, Riley S, Kelly JW.   +5 more
europepmc   +1 more source

Integrative structural profiling and ligand optimisation across the transthyretin mutational landscape. [PDF]

NPJ Syst Biol Appl
Lomoio U, Carbonari V, Giorgi FM, Ortuso F, Lió P, Veltri P, Guzzi PH.   +6 more
europepmc   +1 more source

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis. [PDF]

Cardiol Ther
Kelly JW.
europepmc   +1 more source

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review. [PDF]

J Clin Med
Wanniarachchige D, Khan S, Pan S.
europepmc   +1 more source

Benefit-risk methodology project:work package 4 report: benefit-risk tools and processes [PDF]

, 2012

core